Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized
by the accumulation of CD207+ dendritic cells (DCs) in inflammatory lesions. Recurrent
BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients
were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207+ DCs.
BRAF-V600E expression in tissue DCs did not define specific clinical risk groups but was
associated with increased risk of recurrence. Strikingly, we found that patients with active …

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically
distinct LCH risk groups | Journal of Experimental Medicine | Rockefeller University Press …
JCB Journal of Cell Biology … Allen; BRAF-V600E expression in precursor versus
differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 9
February 2015; 212 (2): 281. doi: https://doi.org/10.1084/jem.…